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Abstract
Background: The clinical course of chronic pancreatitis is still unpredictable, which relates to the
lack of the availability of a clinical classification. Therefore, patient populations cannot be compared,
the course and the outcome of the disease remain undetermined in the individual patient, and
treatment is not standardized.
Aim: To establish a clinical classification for chronic pancreatitis which is user friendly, transparent,
relevant, prognosis- as well as treatment-related and offers a frame for future disease evaluation.
Methods: Diagnostic requirements will include one clinical criterion, in combination with well
defined imaging or functional abnormalities.
Results: A classification system consisting of three stages (A, B and C) is presented, which fulfils
the above-mentioned criteria. Clinical criteria are: pain, recurrent attacks of pancreatitis,
complications of chronic pancreatitis (e.g. bile duct stenosis), steatorrhea, and diabetes mellitus.
Imaging criteria consist of ductal or parenchymal changes observed by ultrasonography, ERCP, CT,
MRI, and/or endosonography.
Conclusion: A new classification of chronic pancreatitis, based on combination of clinical signs,
morphology and function, is presented. It is easy to handle and an instrument to study and to
compare the natural course, the prognosis and treatment of patients with chronic pancreatitis.
Introduction
Chronic pancreatitis is a heterogeneous disorder with a
clinical spectrum that encompasses pain, loss of exocrine
pancreatic function, diabetes mellitus and various com-
plications usually involving organs adjacent to the pan-
creas[1,2]). The disease may present clinically either with
an individual symptom or a combination of symptoms
associated with loss of pancreatic function. The single
most frequent symptom of chronic pancreatitis is pain,
either in the form of intermittent episodes or in a more
chronic or persistent pattern[3-5].
The natural history of chronic pancreatitis is usually char-
acterized by progression of tissue damage and various
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degrees of exocrine and endocrine pancreatic insuffi-
ciency, which will become apparent over time[4,6,7]. Var-
ious well-defined complications may occur at any stage
during the course of the disease. However, independent of
the underlying etiology, chronic pancreatitis evolves
toward the same end stage, i.e., pancreatic fibrosis[8,9].
It is general knowledge that the terminal stage of chronic
pancreatitis results in a loss of organ function, with the
clinical manifestations of maldigestion and diabetes mel-
litus[10]. However, there is little knowledge of the early
structural and functional abnormalities because the cur-
rent diagnostic imaging procedures are not sensitive
enough to visualize them and histology is normally not
available in these early stages[11-13].
The presentation of very distinct clinical symptoms and
the frequent complexity of their associations require a
well-differentiated therapeutic approach. Current thera-
pies in the management of chronic pancreatitis include
conservative measures (analgesics, anti-inflammatory
agents, enzyme replacement), endoscopic interventions
as well as surgical procedures[14-18]. However, there are
no guidelines for the treatment of various alterations of
chronic pancreatitis, and therefore therapy is generally
individualized, depending on the personal experience of
the treating clinician and local logistics. Evidence-based
recommendations for the treatment of chronic pancreati-
tis are currently lacking, but need to be implemented in
the future to address the key question of whether the nat-
ural course of chronic pancreatitis can be positively influ-
enced by different interventions, including surgery.
There is considerable controversy, for example, over the
management of pain in chronic pancreatitis, with some
clinicians preferring long-term conservative management,
others advocating interventional endoscopies, and still
others making a plea for surgical procedures[6,14,19,20].
More than half a century after the first and classical
description of chronic pancreatitis by Comfort and cow-
orkers, we are still searching for an instrument which will
allow us to test and compare different therapeutic options
for this disease[21].
Attempts to classify chronic pancreatitis
The main reason for the lack of guided strategies in the
therapeutic management of chronic pancreatitis is the
absence of a clinically applicable classification of chronic
pancreatitis. In the past, several classifications have cer-
tainly contributed to a better understanding of the patho-
genesis and pathophysiology of chronic pancreatitis. The
meetings in Marseilles 1963 and 1984 and in Rome 1985
added a great deal of information to our knowledge of the
pathogenesis and evolution of chronic pancreatitis[22-
24]. However, other than the designation of chronic alco-
holic pancreatitis as a special entity of chronic obstructive
pancreatitis of various etiologies, no further attempt to
design a clinically relevant system of staging was under-
taken[23]. In another meeting, in Cambridge 1984, the
participants focused on using the emerging imaging pro-
cedure of that time, ERCP, to stage the changes in chronic
pancreatitis, but again there was no staging of the clinical
manifestations and no attempt was made to correlate clin-
ical aspects with imaging[25,26].
In recent years it has become quite evident that clinical
decisions cannot be based on the type and the degree of
morphological abnormalities, but need to be based on
clinical findings (pain, complications, pseudocysts, etc.)
in combination with findings in the functional, diagnostic
and imaging procedures[27].
The concept of selecting an endoscopic or a surgical pro-
cedure based primarily on the type of morphological
complications has contributed significantly to the current
controversy over management of pain in chronic pancre-
atitis[28,29].
Amman et al., organizing a symposium 1996, attempted
to introduce clinical aspects into a classification of chronic
pancreatitis, with special consideration of acute and
chronic alcoholic pancreatitis[30]. The main result of that
meeting was a better insight into different evolutional pat-
terns of alcoholic pancreatitis, but again it was limited to
alcoholic etiology and did not attempt to classify the dis-
ease in different clinical stages. Ramesh published 2002 a
classification which was based on a ABC Classification
system too, but included too many and redundant sub-
classification parameters and therefore the classification
did not gained widespread use[31]. The Manchester clas-
sification which was presented in 2006, used the ABC
grading system as well but had difficulties in resembling
the natural course of chronic pancreatitis and therefore
needs to be further evaluated[32]. The M-ANNHEIM clas-
sification presented by Schneider et al. in 2007 tried to
describe chronic pancreatitis very detailed and therefore it
might be difficult to use in clinical practice[33].
The need for a new clinical classification of chronic 
pancreatitis
In order to combine clinical experience in the field of
chronic pancreatitis with progress in diagnostic methods
and new molecular technologies for the assessment of
chronic pancreatitis, a classification of chronic pancreati-
tis based on key clinical aspects is crucial[34-36]. This
classification would not only allow us to develop a com-
mon language for the description of this disease, but also
to study the dynamics of disease evolution and to com-BMC Gastroenterology 2009, 9:93 http://www.biomedcentral.com/1471-230X/9/93
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pare the role of different etiologies in the appearance of
chronic pancreatitis.
Such a classification needs to be applicable and transpar-
ent in all parts of the world, and would allow for compar-
ison of experiences and serve as a basis for disease staging
in clinical trials in chronic pancreatitis. A new classifica-
tion should first be validated to determine whether it is
suitable to be applied to the majority of patients with
chronic pancreatitis, and then the value of such a classifi-
cation needs to be tested in our understanding of the nat-
ural course in different etiologies (progression, arrest,
regression) and most importantly, to study the clinical
outcome when different therapeutic strategies are applied.
In suggesting a new classification of CP, we propose a def-
inition of chronic pancreatitis and disease staging based
on key clinical features in association with various find-
ings obtained in current imaging techniques. Our concept
for a new classification will include a rationale adopted
from a liver-pancreas analogy, and will take into account
established knowledge as well as the differing treatment
approaches commonly used today.
Liver-pancreas analogy in fibrogenesis
From a standpoint of morphology/histology, chronic
pancreatitis evolves in a similar manner as chronic hepa-
titis, i.e. liver fibrosis/liver cirrhosis. In both diseases,
independent of the etiology, the chronic inflammatory
process results in a final morphologic picture of fibrosis/
cirrhosis[37,38]. Fibrosis/cirrhosis leads to increasing
functional impairment over time and finally to complete
functional loss in both organs. Also, the progression from
fibrosis/cirrhosis to cancer has been described in both
conditions[39,40]. However, the clinical picture differs
inasmuch as chronic pancreatitis is dominated by pain in
addition to exocrine and endocrine functional loss.
As a hypothesis we suggest that chronic pancreatitis
begins with episodes of acute inflammation with or with-
out clinical appearance, analagous to the acute, often also
clinically in apparent evolution of hepatitis from an acute
into a chronic disease state (i.e., hepatitis C).
Recently, almost identical mechanisms have been
described in the pathogenetic evolution of pancreatic and
hepatic fibrogenesis, with a central role assigned to stel-
late cells for remodeling and repair of the inflammatory
damage[41-44]. For staging of chronic liver disease, i.e.,
liver cirrhosis, the Child-Pugh classification [30], based
on functional impairment and complications, has
received world-wide validation and acceptance[45]. How-
ever, such a grading system has not yet been proposed in
chronic pancreatitis and/or end-stage pancreatic fibrosis.
Facts and state-of-the-art knowledge in chronic 
pancreatitis
1) Different etiologies lead to chronic pancreatitis with
the end result of pancreatic fibrosis.
2) There are no serologic or blood markers available to
diagnose/stage (grade) the disease.
3) Pathognomonic lesions of the ductular system and
parenchyma are detectable by imaging.
4) Loss of exocrine and endocrine function develops dur-
ing progression of the disease.
5) The end stage is characterized by steatorrhea and insu-
lin-dependent diabetes mellitus.
6) Several characteristic complications of chronic pancre-
atitis are known such as common bile duct, duodenal,
main pancreatic duct and vascular obstruction/stenosis.
7) Chronic pancreatitis represents a risk factor for pancre-
atic cancer.
8) Overall life expectancy is reduced.
Unresolved issues in chronic pancreatitis
1) The relationship between acute pancreatitis and
chronic pancreatitis is not completely defined.
2) The issues whether in chronic pancreatitis disease pro-
gression, arrest and regression of functional and morpho-
logic findings occur is debated.
3) Diagnosis of early chronic pancreatitis by imaging is
not established.
4) The role and validity of exocrine pancreatic function
tests in the diagnosis is not established.
5) The pathogenesis of pain is at least multifactorial and
not defined.
6) The burn-out hypothesis is still debated and not
defined with regard to time evolution in different etiolo-
gies.
Table 1: Clinical criteria
Clinical Criteria
▪pain
▪attacks of acute pancreatitis
▪complications of CP (see Table 2)
▪steatorrhea
▪diabetis mellitusBMC Gastroenterology 2009, 9:93 http://www.biomedcentral.com/1471-230X/9/93
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7) There is disagreement over whether to use enzyme
treatment to influence pain.
8) The role of endoscopic intervention is not defined
under evidence-based criteria.
9) The role of surgery is not defined under evidence-based
criteria.
Proposal for a clinically-based classification of 
chronic pancreatitis
Definition of chronic pancreatitis (diagnosis)
For the diagnosis of chronic pancreatitis we require at
least one clinical criterion (Table 1) such as pain, (recur-
rent) attacks of acute pancreatitis, steatorrhea, diabetes
mellitus or well-defined complications (Table 2) of
chronic pancreatitis. These clinical criteria must be accom-
panied by well-defined abnormalities in imaging findings
(Table 3) or in a direct pancreatic function test.
The etiology of chronic pancreatitis needs to be specified
according to Table 4.
Staging/classification of chronic pancreatitis (Stages A, B, 
C)
Specific definition of chronic pancreatitis stage A
Stage A is the early stage of chronic pancreatitis where
complications have not yet appeared and the clinical exo-
crine and endocrine function is preserved. Subclinical
signs (impaired glucose tolerance, reduced exocrine func-
tion but without steatorrhea) might already be apparent.
Stage A is accepted under the following conditions:
Pain of any type and degree and/or attacks of acute pan-
creatitis, no complications (Table 2), no steatorrhea, no
insulin-dependent diabetes mellitus.
Specific definition of chronic pancreatitis stage B
Stage B is the intermediate stage where chronic pancreati-
tis has led to complications but clinical exocrine and
endocrine function is still preserved.
The type of complication is specified (e.g., stage B, bile
duct)
Stage B is accepted under the following conditions:
Patients with complications (Table 2) but without steator-
rhea or diabetes mellitus.
Specific definition of chronic pancreatitis stage C
Stage C is the end stage of chronic pancreatitis, where pan-
creatic fibrosis has led to clinical exocrine and/or endo-
crine pancreatic function loss (steatorrhea and/or diabetes
mellitus). Complications of chronic pancreatitis might or
might not be present.
The type of exocrine and/or endocrine pancreatic function
loss is specified (e.g., stage C, steatorrhea).
Stage C can be sub classified into three categories:
C1: Patients with endocrine function impairment
C2: Patients with exocrine function impairment
Table 3: Imaging criteria for chronic pancreatitis
Imaging criteria for chronic pancreatitis
Ductal changes: Irregularity of the main pancreatic duct or side branches ± intraductal filling defects, calculi, duct obstruction 
(stricture), duct dilatation (>3 mm)
Parenchymal changes: General or focal enlargement of the gland, cysts, calcifications, heterogenous reflectivity.
Table 2: Definition of complications
Definition of complications
bile duct obstruction/stenosis with cholestasis or jaundice
▪duodenal obstruction/stenosis with clinical signs
▪vascular obstruction/stenosis with clinical or morphological signs of portal/splenic vein hypertension
▪pancreatic pseudocysts with clinical signs (compression of adjacent organs, infection, bleeding, etc.)
▪pancreatic fistula (internal or external)
▪pancreatogenic ascites
▪other rare complications related to organs in vicinity (i.e., colonic stenosis,
splenic pseudocyst, etc.)BMC Gastroenterology 2009, 9:93 http://www.biomedcentral.com/1471-230X/9/93
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C3: Patients with exocrine/endocrine function impair-
ment and/or complications as they are defined in table 2.
Stage C is accepted under the following conditions:
Patients with clinical manifestation of end-stage func-
tional impairment with or without complications.
Classification arrangement
The diagnosis of chronic pancreatitis is defined by the
requested criteria (Table 1 + 3 ). The diagnosis is supple-
mented by the etiology (Table 4). This determination is
then supplemented by the staging, potential complica-
tions (e.g., bile duct) and potential function loss (e.g.,
steatorrhea).
For example:
chronic pancreatitis (alcohol), stage A
chronic pancreatitis (ideopathic), stage B, bile duct
chronic pancreatitis (tropical), stage C
Clinical evaluation of the classification
To get a first impression of the clinical practicability of the
new classification we have evaluated 191 patients who
were operated at the Department of General Surgery, Uni-
versity of Heidelberg and followed up for a period up to 3
years. The study was performed in line with the guidelines
of the Declaration of Helsinki, and each patient was asked
to give written informed consent for data collection as
well as for publication of data in an anonymous manner.
The median age of the patients was 49 years (40a/58a)
(25th/75th  quarter). The demographic details of the
patients are summarized in table 5. The type of operations
are given in table 6. Patients were followed-up and
restaged according to the new classification every 6
months. The classification could be applied to all patients
and was easy to use. The majority of the patients were
operated because of a complication (Grade B) of chronic
pancreatitis (68.1%), whereas 25.7% of the patients had
pancreatic insufficiency (Grade C). Interestingly, only 12
patients (6.3%) had as the only indication for operation
pain, which could not be handled by medical therapy
(Grade A). This finding is supported by a recent study
which demonstrated a comparable incidence of complica-
tions leading to surgery[46]. A quite stable rate of 3-4.5%
Table 6: Indication and type of operation of patients with chronic 
pancreatitis who were operated at the Department of General 
Surgery, University of Heidelberg
N = 191 N [%]
Indication for operation
pain 110 57.5
stenosis of Choledochus 22 11.5
inflam. Tumor 54 28.3
pseudocyst 26 13.6
duodenal Stenosis 5 2.6
rez. Pankreatitis 26 13.6
stenosis of pancreatic duct 23 12.0
other complications 15 7.9
Type of operation
duodenum preserving pancreatic head resection 86 45.0
classical Whipple 12 6.3
pp-Whipple 47 24.6
segmental resection 11 5.8
pancreatic left resection 11 5.8
pancreatico-jejunostomy 10 5.2
bili-digestive anastomosis 4 2.1
other 10 5.2
Table 4: Etiology of chronic pancreatitis
Etiology of chronic pancreatitis
▪alcohol
▪idiopathic (unknown origin)
▪hereditary
▪autoimmune or in combination with specific diseases (Crohn's, PBC)
▪tropical
▪cystic fibrosis
▪obstructive (pancreatic duct)
▪drugs
Table 5: Patients with chronic pancreatitis who were operated at 
the Department of General Surgery, University of Heidelberg
N = 191 N [%]
Gender
male 135 70.7
female 56 29.3
Etiology
alcohol 55 33.7
idiopathic 48 29.4
biliary 16 9.8
other 44 27.0
Mortality
alive 184 96.3
mortality (other disease) 5 2.6
mortality (reason CP) 2 1.0BMC Gastroenterology 2009, 9:93 http://www.biomedcentral.com/1471-230X/9/93
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of the patients developed additional complications
within the 6 months follow-up intervals. With a longer
duration of the disease more patients developed a pancre-
atic insufficiency - 25.7% preoperative to 57.1% after 3a.
(Table 7; Figure 1)
Discussion
The present article proposes a new clinical classification of
chronic pancreatitis, which is practically easy to use and
applicable for all etiologies of chronic pancreatitis.
The key concern in the management of CP arises from the
inability to compare CP patients with different etiologies
on different continents and from the absence of a staging/
disease evolution system of chronic pancreatitis. For dec-
ades debate has continued, centering on the optimal ther-
apeutic options. Conservative, endoscopic and surgical
treatment concepts compete without being able to pro-
vide evidence of their validity at any time in the course of
the disease[19,47-49].
Patients with CP are treated according to local expertise
and bias, and not based on evidence-based studies. There-
fore, a new classification for the definition and staging of
CP is urgently needed and should serve as a basis to learn
about and better understand the natural course of the dis-
ease and the effects of different interventions.
As an example of the current confusion, depending upon
the different interpretations of pain mechanisms in CP,
several authors advocate endoscopic interventions, i.e.,
stenting of the common bile duct or the main pancreatic
duct or extracorporeal shock wave lithotripsy (ESWL) of
pancreatic stones, whereas others deny this
approach[12,28,50-52]. Furthermore, in the surgical
world the debate continues about drainage opera-
tions[35-37] versus resection [17,38-41] in the manage-
ment of pain and complications of CP[20,29,53-58]. In
the interest of the patient, we need to carefully select, ana-
lyze and compare these measures. However, in order for a
new classification to be applied, it needs to be applicable
in centers around the world, and reliable assessment and
comparison of the patients should be possible.
The new classification, which we propose, seems to fulfill
these requirements. It is simple, reproducible and based
upon clinical signs and modern imaging techniques as
well as pancreatic function, and most importantly, it is
also based upon our current still limited knowledge about
the natural course of CP. We have taken into account the
liver cirrhosis classification (Child-Pugh) as a successful
model, an analogy that seems applicable in CP as well,
because most recently, several authors have described
common mechanisms for liver and pancreatic fibrogene-
sis with a resulting loss in organ function at the end stage
of both diseases[41-43,59,60].
The future task should be to establish an international
working group and to prospectively evaluate the clinical
significance of the proposed classification. This procedure
should enable us both to validate this classification and to
study the course of CP with and without treatment
aspects.
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